Aquestive Therapeutics, Inc. (AQST) Stock Analysis
Aquestive is a high-risk, high-upside biotech inflection story: a de-risked balance sheet and differentiated needle-free epinephrine film could unlock major value if Anaphylm clears its final FDA usability hurdles.
Overview
Aquestive Therapeutics is at a pivotal inflection point after transforming into a proprietary specialty pharma company. Q1 2026 showed strong revenue growth, sharply reduced losses, and a materially strengthened balance sheet. The Anaphylm CRL appears addressable, centered on human factors, packaging, and supportive PK rather than efficacy or manufacturing. With FDA Type A meeting alignment, planned Q3 2026 resubmission, and a $150 million Oaktree facility supporting launch readiness, Aquestive offers high upside—but remains highly dependent on flawless regulatory execution.